Compare GNK & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNK | FTRE |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 732.0M | 864.4M |
| IPO Year | 2005 | N/A |
| Metric | GNK | FTRE |
|---|---|---|
| Price | $18.77 | $14.58 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 8 |
| Target Price | ★ $19.00 | $11.64 |
| AVG Volume (30 Days) | 568.7K | ★ 1.3M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 7.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $331,332,000.00 | ★ $2,759,900,000.00 |
| Revenue This Year | N/A | $3.17 |
| Revenue Next Year | $4.34 | $0.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.88 |
| 52 Week Low | $11.20 | $3.97 |
| 52 Week High | $19.60 | $23.22 |
| Indicator | GNK | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 60.52 | 69.45 |
| Support Level | $18.64 | $14.06 |
| Resistance Level | $19.45 | $14.96 |
| Average True Range (ATR) | 0.40 | 0.98 |
| MACD | 0.01 | 0.29 |
| Stochastic Oscillator | 67.86 | 91.60 |
Genco Shipping & Trading Ltd is an international shipping company specializing in the transportation of iron ore, coal, grain, steel products and other drybulk cargoes. It is involved in the ocean transportation of drybulk cargoes. The company operates in one segment, with two reportable segment: Major and Minor bulk fleet. It generates revenue through time charter agreements, spot market voyage charters, pool agreements and spot market-related time charters. oyage revenues also include the sale of bunkers consumed during short-term time charters pursuant to the terms of the time charter agreement.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.